A survey conducted by Datafolha for the pharmaceutical company Eli Lilly has revealed that Alzheimer's disease is the second most feared illness among Brazilians, only behind cancer. According to the survey results, which were released on Monday, 75% of participants expressed that cancer was their top concern, while 13% cited Alzheimer’s as the most dreaded diagnosis, followed closely by AIDS at 9% and Parkinson's at just 1%. This highlights a significant public perception of the disease's severity.

The research involved responses from 2,002 individuals over the age of 16 from all regions of Brazil in December of last year. The majority of those surveyed are cognizant of Alzheimer's, with 4 in 10 respondents knowing someone affected by the disease. This awareness contrasts with the stigma surrounding Alzheimer's, as many still fear the cognitive decline associated with it. Experts, including Celene Pinheiro, president of the Brazilian Alzheimer Association, emphasize that this fear is rooted in a lack of understanding about the disease and its implications.

The findings underline the urgent need for better education and awareness campaigns regarding Alzheimer's to diminish stigma and fear. As more Brazilians express concerns over Alzheimer's, there is an opportunity for health organizations to inform the public, encourage early detection, and support those living with the disease. By addressing these fears and elevating the conversation about cognitive health, society can work towards a more informed understanding of Alzheimer's and its impact on families.